MyFinsight
Home
Compare
Blog
About
Proceeds from issuance of
convertible notes
$35,000K
Proceeds from issuance of
common stock upon...
$231K
Net cash provided by
financing activities
$33,949K
Canceled cashflow
$1,282K
Net (decrease)
increase in cash, cash...
-$14,511K
Canceled cashflow
$33,949K
Stock-based compensation
expense
$4,121K
Accrued expenses and
other current...
$441K
Non-cash lease expense
$281K
Amortization of debt discount
and issuance costs
$275K
Prepaid expenses and
other current assets
-$198K
Depreciation
$99K
Payment of deferred
initial public offering...
$1,282K
Net cash used in
operating activities
-$48,350K
Canceled cashflow
$5,415K
Net cash used in
investing activities
-$110K
Net loss
-$48,758K
Other assets
$3,262K
Accounts payable
-$1,449K
Operating lease
liabilities
-$296K
Purchases of property and
equipment
$110K
Back
Back
Cash Flow
Latigo Biotherapeutics, Inc. (LTGO)
Latigo Biotherapeutics, Inc. (LTGO)
source: myfinsight.com